Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
Crossref DOI link: https://doi.org/10.1186/s12883-017-0948-5
Published Online: 2017-09-11
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Adams, David
Suhr, Ole B.
Dyck, Peter J.
Litchy, William J.
Leahy, Raina G.
Chen, Jihong
Gollob, Jared
Coelho, Teresa
Funding for this research was provided by:
Alnylam Pharmaceuticals